Navigating the Volatility of Cogent Biosciences Inc’s (COGT) Stock

The stock of Cogent Biosciences Inc (COGT) has gone up by 16.78% for the week, with a -6.64% drop in the past month and a 14.80% rise in the past quarter. The volatility ratio for the week is 7.81%, and the volatility levels for the past 30 days are 7.01% for COGT. The simple moving average for the last 20 days is 1.97% for COGT stock, with a simple moving average of -23.22% for the last 200 days.

Is It Worth Investing in Cogent Biosciences Inc (NASDAQ: COGT) Right Now?

Company’s 36-month beta value is 1.57.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for COGT is 87.22M, and currently, short sellers hold a 11.05% ratio of that floaft. The average trading volume of COGT on April 03, 2024 was 2.24M shares.

COGT) stock’s latest price update

Cogent Biosciences Inc (NASDAQ: COGT)’s stock price has plunge by -2.17relation to previous closing price of 6.90. Nevertheless, the company has seen a 16.78% surge in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-02-05 that Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET

Analysts’ Opinion of COGT

Many brokerage firms have already submitted their reports for COGT stocks, with Robert W. Baird repeating the rating for COGT by listing it as a “Neutral.” The predicted price for COGT in the upcoming period, according to Robert W. Baird is $8 based on the research report published on February 26, 2024 of the current year 2024.

Citigroup, on the other hand, stated in their research note that they expect to see COGT reach a price target of $11. The rating they have provided for COGT stocks is “Buy” according to the report published on February 08th, 2024.

Wedbush gave a rating of “Neutral” to COGT, setting the target price at $5 in the report published on December 11th of the previous year.

COGT Trading at 5.43% from the 50-Day Moving Average

After a stumble in the market that brought COGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.00% of loss for the given period.

Volatility was left at 7.01%, however, over the last 30 days, the volatility rate increased by 7.81%, as shares sank -4.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +47.06% upper at present.

During the last 5 trading sessions, COGT rose by +16.78%, which changed the moving average for the period of 200-days by -47.47% in comparison to the 20-day moving average, which settled at $6.60. In addition, Cogent Biosciences Inc saw 14.80% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at COGT starting from Fairmount Funds Management LLC, who purchase 800,000 shares at the price of $12.00 back on Jun 09 ’23. After this action, Fairmount Funds Management LLC now owns 3,272,124 shares of Cogent Biosciences Inc, valued at $9,600,000 using the latest closing price.

Stock Fundamentals for COGT

The total capital return value is set at -0.76. Equity return is now at value -74.94, with -62.65 for asset returns.

Based on Cogent Biosciences Inc (COGT), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -8.15. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 44.76.

Currently, EBITDA for the company is -204.54 million with net debt to EBITDA at 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.09.

Conclusion

In a nutshell, Cogent Biosciences Inc (COGT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts